Silas Inman

AAV2/5-OPTIRPE65 showed improvements in vision-guided mobility, retinal sensitivity, and foveal-driven visual function for patients with RPE65-associated retinal dystrophy.

MET inhibitor capmatinib may hold promise for a small subtype of patients with a non-small cell lung cancer, according to new ASCO 2019 findings.

The FDA has approved the first-in-class CGRP monoclonal antibody erenumab for the prevention of migraines in adults, based on findings from three clinical trials.

Intravitreal aflibercept injection showed early signs of activity for patients with moderately severe to severe nonproliferative diabetic retinopathy.

The novel immune-based treatment IMCgp100 demonstrated a 1-year survival rate of 73% for patients with heavily pretreated, advanced uveal melanoma.

Voretigene neparvovec demonstrated sustained improvements in vision for patients with biallelic RPE65-mutation–associated inherited retinal disease.

Outcomes for patients with nAMD in the real-world were inferior to randomized controlled trials due to significant undertreatment.

An automated artificial intelligence-based system was approximately 70% accurate at predicting optimal retreatment intervals for nAMD.

Brolucizumab, which could be given every 12 weeks, showed non-inferior improvements in BCVA when compared with aflibercept every 8 weeks.

Use of a 0.18 mg fluocinolone acetonide intravitreal insert effectively lowered the rate of uveitis recurrences and cumulative total recurrent episodes.

A fully automated artificial intelligence-based system could effectively classify function and potency of cell therapy.

A wave of novel gene therapies is on the horizon as treatments for patients with retinitis pigmentosa.

Evolocumab reduced LDL-C resulting in fewer CV events for patients with peripheral artery disease.

The FDA has approved aripiprazole tablets with a sensor to digitally track whether patients have taken their medication.

A restrictive transfusion strategy was non-inferior versus a liberal approach for cardiac surgery.

Ibudilast slowed the rate of brain atrophy by 48% without inducing significant toxicity for progressive MS.

Ozanimod reduced the annualized relapse rate and lowered the number of T2 lesions versus interferon beta-1a for RMS.

Ozanimod reduced ARR and showed marked reductions in T2 lesions compared with interferon β-1a for RMS.

Alemtuzumab showed significant reductions in MRI lesions and slowed brain volume loss in 5-year results for RRMS.

Nearly all patients with relapsing multiple sclerosis treated with ublituximab remained relapsed free after 24 weeks.

MD1003 led to a pseudo-atrophy phenomenon that was likely related to remyelination.

The US Food and Drug Administration has approved meropenem-vaborbactam as a treatment for adult patients with complicated urinary tract infections, including pyelonephritis.

Intravitreal ranibizumab significantly improved BCVA compared with vPDT for patients with myopic CNV, often after only 1 or 2 injections.

Aflibercept reduced macular edema, microaneurysms, leakage, and ischemic burden while improving VA for patients with DME or RVO.

Sirolimus plus aflibercept showed marked reduction in intraretinal and subretinal fluid compared with aflibercept alone for patients with wet AMD.

ICON-1 plus ranibizumab effectively reduced CNV size and led to complete drying of the retina for some patients with wet AMD.

Intravitreal bevacizumab effectively lowered the risk of retinal detachment recurrence after primary pars plana vitrectomy.

Improvements in visual acuity were less pronounced in the "real-world" setting compared with randomized trials for diabetic macular edema.

RGX-314 could help to alleviate the overall treatment burden for patients with wet age-related macular degeneration via a one-time subretinal injection.